Click here - to use the wp menu builder

Less than 1 min.Read

Prepayments, Realkredit Danmark A/S

By Investing Today

April 28, 2025

Nasdaq Copenhagen A/S

Executive Management
Bernstorffsgade 40
DK-1577 København V
www.rd.dk

Telephone +45 7012 5300

28 April 2025

Company Announcement No 36/2025

Prepayments, Realkredit Danmark A/S

Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as of Friday 25 April 2025. Please find the data in the attached file.

The information will also be available on www.rd.dk.

Yours sincerely

The Executive Management

Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068.

Attachments

Nr. 36_Ekstraordinaere indfrielser_uk
Bilag til selskabsmeddelelse nr 36-2025

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Form 8.5 (EPT/RI) – Alliance Pharma plc

AirNet Announces Termination of Deposit Agreement

Prepayments, Realkredit Danmark A/S

Decisions taken by Sanoma Corporation’s Annual General Meeting and Board of Directors

Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment

Comstock to Host First Quarter 2025 Earnings and Business Update Call

Regeneron Reports First Quarter 2025 Financial and Operating Results

AgEagle Aerial Systems Receives Non-Compliance Notice from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Topics

Decisions taken by Sanoma Corporation’s Annual General Meeting and Board of Directors

Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment

Comstock to Host First Quarter 2025 Earnings and Business Update Call

Regeneron Reports First Quarter 2025 Financial and Operating Results

AgEagle Aerial Systems Receives Non-Compliance Notice from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Related Articles

Decisions taken by Sanoma Corporation’s Annual General Meeting and Board of Directors

Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment

Comstock to Host First Quarter 2025 Earnings and Business Update Call

Regeneron Reports First Quarter 2025 Financial and Operating Results

AgEagle Aerial Systems Receives Non-Compliance Notice from NYSE American and Makes NYSE American Section 610(b) Public Announcement

Company

Headlines

Decisions taken by Sanoma Corporation’s Annual General Meeting and Board of Directors

Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment

Comstock to Host First Quarter 2025 Earnings and Business Update Call

Regeneron Reports First Quarter 2025 Financial and Operating Results

Newsletter